Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 135Thoracic 38Gynecologic 31Breast 25Head & Neck 21Genitourinary 21Sarcoma 8Dermatologic 8Endocrine 5Other solid neoplasm 3CNS 3NET 2Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 879Leukemia, Lymphocytic, Chronic, B-Cell 560Leukemia 426Hematologic Neoplasms 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Myelodysplastic Syndromes 302Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Lymphoma, Non-Hodgkin 224Recurrence 222Lymphoma 196Neoplasms 195Multiple Myeloma 129Lymphoma, Mantle-Cell 119Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Follicular 114Leukemia, Myelomonocytic, Chronic 89Lymphoma, B-Cell 88Lymphoma, B-Cell, Marginal Zone 85Leukemia, B-Cell 79Burkitt Lymphoma 64Leukemia, Myeloid, Chronic-Phase 57Waldenstrom Macroglobulinemia 56Leukemia, Myeloid 53Hodgkin Disease 47Hematologic Diseases 47Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 45Myeloproliferative Disorders 40Primary Myelofibrosis 39Bronchiolitis Obliterans Syndrome 35Anemia, Refractory, with Excess of Blasts 32

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡